Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …

Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin,
carboplatin and oxaliplatin, a variety of other metal-based anti-cancer compounds are being …

The antimetastatic ruthenium (II) compounds [Ru (η6-p-cymene) Cl2 (PTA)](PTA= 1, 3, 5-
triaza-7-phosphaadamantane)(RAPTA-C) and [Ru (η6-toluene) Cl2 (PTA)](RAPTA-T), as …

Emergence of resistance in cancer cells and dose-limiting side effects severely limit the
widespread use of platinum (Pt) anticancer drugs. Multi-action hybrid anticancer agents that …

A ruthenium (II)–arene complex with a perfluoroalkyl-ligand was found to display remarkable
selectivity toward cancer cells. IC50 values on several cancer cell lines are in the range of …

Antiangiogenic therapy is considered to be a promising strategy for the treatment of cancers.
VEGF and its receptors are important angiogenic factors involved in tumor growth. In the …

Background Previous studies suggest that certain transition metal complexes, such as
cisplatin, are efficacious for treating various cancer types, including ovarian, lung, and …

Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct
metal species into a single molecule. The ruthenium–gold (Ru–Au) family of compounds …

Both metal complexes and organic molecules are widely used for the treatment of various
diseases including cancer–in addition to surgery and radiotherapy. Recent years have …

Combination therapy targeting both tumor growth and vascularization is considered to be a
cornerstone for colorectal carcinomas (CRC) treatment. However, the major obstacles of …